WAKIX® (pitolisant) Preliminary Net Revenue of ~$168 Million for Fourth Quarter and ~$582 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively Average Number of Patients on WAKIX Increased to ~6,150 2024 Net Product Revenue Projected Between $700 –$720 Million $50 Million Common Stock Repurchase in Fourth Quarter Bringing 2023 Total to $100… Continue reading HARMONY BIOSCIENCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2023 NET PRODUCT REVENUE INCREASES MORE THAN 30 PERCENT; PROVIDES 2024 NET PRODUCT REVENUE GUIDANCE
Tag: Morgan
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
– Numerous value-driving commercial, regulatory and pipeline milestones anticipated – CARLSBAD, Calif., Jan. 8, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company’s 2023 achievements and previewed a number of important milestones expected in 2024. Ionis will provide a business update at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January… Continue reading Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
Kongsberg Aviation Maintenance Services AS selects IFS Cloud to streamline operations and strengthen asset reliability
IFS Cloud’s ERP, MRO solution to enable Kongsberg company to increase automation driving efficiency and build long-term asset resilience and reliability. LONDON, Jan. 8, 2024 /PRNewswire/ — IFS, the global cloud enterprise software company, today announced that Kongsberg Aviation Maintenance Services AS (KAMS), a leading supplier of maintenance, repair and overhaul (MRO) services within the aviation… Continue reading Kongsberg Aviation Maintenance Services AS selects IFS Cloud to streamline operations and strengthen asset reliability
Calliditas to present at JP Morgan Healthcare Conference
STOCKHOLM, Jan. 7, 2024 /PRNewswire/ — Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that management will present at and participate in the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place January 8-11, 2024, in San Francisco, California. Calliditas will present an update on the company at 7:30 am PT… Continue reading Calliditas to present at JP Morgan Healthcare Conference
Calliditas to present at JP Morgan Healthcare Conference
STOCKHOLM, Jan. 7, 2024 /PRNewswire/ — Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that management will present at and participate in the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place January 8-11, 2024, in San Francisco, California. Calliditas will present an update on the company at 7:30 am PT… Continue reading Calliditas to present at JP Morgan Healthcare Conference
IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance
SOUTH SAN FRANCISCO, Calif., Jan. 7, 2024 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 corporate guidance and program updates. 42nd Annual J.P. Morgan Healthcare ConferenceTuesday, January 9th, 2024… Continue reading IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
Strong revenue generation in Q4 2023, including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain Encouraging first results from first-in-human trial of HNSA-5487, Hansa’s lead candidate from the NiceR program for repeat dosing Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s SRP-9001 in DMD … Continue reading Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
Strong revenue generation in Q4 2023, including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain Encouraging first results from first-in-human trial of HNSA-5487, Hansa’s lead candidate from the NiceR program for repeat dosing Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s SRP-9001 in DMD … Continue reading Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
Cerapedics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
WESTMINSTER, Colo., Jan. 5, 2024 /PRNewswire/ — Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone repair, today announced that Valeska Schroeder, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference. The company presentation will take place on Monday, January 8, 2024, at 5:00 PM PST… Continue reading Cerapedics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
—ARIKAYCE® (amikacin liposome inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudited Global Net Product Sales of Approximately $305.2 Million— —2024 Global ARIKAYCE Revenues Expected to be Between $340 Million and $360 Million, Reflecting Double-Digit Growth Compared to 2023— —Topline Data from the Phase 3 ASPEN Study of Brensocatib… Continue reading Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference